A Phase 4 Pragmatic, Randomized Trial to Evaluate the Effectiveness of mRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adults Aged 50-64 Years Without Risk Factors for Severe COVID-19

Publication date: Dec 11, 2025

The purpose of this pragmatic randomized trial is to evaluate the vaccine effectiveness of the COVID-19 vaccine, mRNA-1273, in adults aged 50-64 years without known risk factors for severe COVID-19 infection. Participants will be randomized 1:1 to either COVID-19 vaccine or no COVID-19 vaccine.

Concepts	Keywords
Danish	Cardiovascular
Kidney	COVID-19
Psychotic	Pragmatic
Vaccine	Registry
	Respiratory
	Respiratory tract disease
	Vaccination

Semantics

Type	Source	Name
disease	MESH	COVID-19
disease	MESH	infection
disease	MESH	Asthma
pathway	KEGG	Asthma
disease	MESH	Cancer
disease	MESH	melanoma
pathway	KEGG	Melanoma
disease	MESH	skin cancer
disease	MESH	Cardiomyopathies
disease	MESH	Cerebrovascular disease
disease	MESH	Chronic kidney disease
disease	MESH	Cystic Fibrosis
disease	MESH	Dementia
disease	MESH	Down syndrome
disease	MESH	Heart failure
disease	MESH	Ischemic heart disease
disease	MESH	Liver disease
disease	MESH	neuromuscular disease
disease	MESH	Psychiatric disease
disease	MESH	Severe obesity
disease	MESH	substance abuse
disease	MESH	Short bowel syndrome
disease	MESH	Respiratory tract disease